CN107206049B - 治疗患1型肝肾综合征的患者的方法 - Google Patents

治疗患1型肝肾综合征的患者的方法 Download PDF

Info

Publication number
CN107206049B
CN107206049B CN201580062745.3A CN201580062745A CN107206049B CN 107206049 B CN107206049 B CN 107206049B CN 201580062745 A CN201580062745 A CN 201580062745A CN 107206049 B CN107206049 B CN 107206049B
Authority
CN
China
Prior art keywords
patient
terlipressin
treatment
iii
hrs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580062745.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN107206049A (zh
Inventor
K·雅米尔
S·C·帕帕斯
J·波滕齐亚诺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mallinckrodt Hospital Products IP Unlimited Co
Original Assignee
Mallinckrodt Hospital Products IP Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallinckrodt Hospital Products IP Unlimited Co filed Critical Mallinckrodt Hospital Products IP Unlimited Co
Priority to CN202111342532.XA priority Critical patent/CN114028536B/zh
Publication of CN107206049A publication Critical patent/CN107206049A/zh
Application granted granted Critical
Publication of CN107206049B publication Critical patent/CN107206049B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
    • A61B5/0205—Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
    • A61B5/024—Measuring pulse rate or heart rate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
    • A61B5/14542—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue for measuring blood gases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M27/00—Drainage appliance for wounds or the like, i.e. wound drains, implanted drains
    • A61M27/002—Implant devices for drainage of body fluids from one part of the body to another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G01N33/4925—Blood measuring blood gas content, e.g. O2, CO2, HCO3
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/01—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
    • G01N2015/016—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N2015/1024—Counting particles by non-optical means

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Physiology (AREA)
  • Medical Informatics (AREA)
  • Surgery (AREA)
  • Food Science & Technology (AREA)
  • Ecology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Dispersion Chemistry (AREA)
  • Zoology (AREA)
CN201580062745.3A 2014-10-24 2015-10-22 治疗患1型肝肾综合征的患者的方法 Active CN107206049B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111342532.XA CN114028536B (zh) 2014-10-24 2015-10-22 治疗患1型肝肾综合征的患者的方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462068357P 2014-10-24 2014-10-24
US62/068,357 2014-10-24
US201562151384P 2015-04-22 2015-04-22
US62/151,384 2015-04-22
PCT/US2015/056861 WO2016065117A1 (en) 2014-10-24 2015-10-22 Method of treating patients with hepatorenal syndrome type 1

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202111342532.XA Division CN114028536B (zh) 2014-10-24 2015-10-22 治疗患1型肝肾综合征的患者的方法

Publications (2)

Publication Number Publication Date
CN107206049A CN107206049A (zh) 2017-09-26
CN107206049B true CN107206049B (zh) 2021-12-07

Family

ID=54478246

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580062745.3A Active CN107206049B (zh) 2014-10-24 2015-10-22 治疗患1型肝肾综合征的患者的方法
CN202111342532.XA Active CN114028536B (zh) 2014-10-24 2015-10-22 治疗患1型肝肾综合征的患者的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202111342532.XA Active CN114028536B (zh) 2014-10-24 2015-10-22 治疗患1型肝肾综合征的患者的方法

Country Status (15)

Country Link
US (2) US10335452B2 (https=)
EP (3) EP3209317B1 (https=)
JP (4) JP6673915B2 (https=)
CN (2) CN107206049B (https=)
AU (1) AU2015335855A1 (https=)
CA (1) CA2965325A1 (https=)
DK (2) DK3978074T3 (https=)
ES (2) ES2987577T3 (https=)
FI (1) FI3978074T3 (https=)
HR (1) HRP20220225T1 (https=)
HU (1) HUE058066T2 (https=)
PL (2) PL3209317T3 (https=)
PT (2) PT3978074T (https=)
SI (1) SI3209317T1 (https=)
WO (1) WO2016065117A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102176900B (zh) 2008-09-17 2017-09-26 克艾思马有限公司 药物组合物和相关的给药方法
US20200046798A1 (en) * 2014-10-24 2020-02-13 Mallinckrodt Hospital Products IP Limited Method of treating patients with hepatorenal syndrome type 1
US20210290725A1 (en) * 2014-10-24 2021-09-23 Mallinckrodt Pharmaceuticals Ireland Limited Method of treating patients with hepatorenal syndrome type 1
HUE058066T2 (hu) * 2014-10-24 2022-06-28 Mallinckrodt Pharmaceuticals Ireland Ltd Terlipressin 1-es típusú hepatorenális szindróma kezelésére
CA3037581A1 (en) * 2016-10-21 2018-04-26 Chiasma, Inc. Terlipressin compositions and their methods of use
KR20220011697A (ko) 2019-05-22 2022-01-28 바이오비에 아이앤씨. 테를리프레신 제형
CN110251469B (zh) * 2019-07-31 2021-11-09 南京康舟医药科技有限公司 一种醋酸特利加压素制剂及其制备方法
US20210128676A1 (en) * 2019-10-30 2021-05-06 Mallinckrodt Hospital Products IP Unlimited Company Method of treating patients with hepatorenal syndrome type 1 and low mean arterial pressure
WO2023183339A1 (en) * 2022-03-22 2023-09-28 Ocelot Bio, Inc. Selective vasopressin receptor agonist for end-stage liver disease
US20240156895A1 (en) * 2022-10-28 2024-05-16 Mallinckrodt Pharmaceuticals Ireland Limited Compositions for improving kidney function in patients with hepatorenal syndrome

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1188443A1 (en) 2000-09-15 2002-03-20 Ferring BV Improved protocol for paracentesis
US7785857B2 (en) * 2006-08-31 2010-08-31 Saint Louis University Protein C variant
GB0617581D0 (en) * 2006-09-07 2006-10-18 Ucl Business Plc Biomarkers for assessing liver function
WO2008112563A1 (en) * 2007-03-09 2008-09-18 Flowmedica, Inc. Acute kidney injury treatment systems and methods
WO2009037586A2 (en) 2007-08-14 2009-03-26 Ferring B.V. Use of peptidic vasopressin receptor agonists
EP2913676A1 (en) * 2008-11-10 2015-09-02 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US9464284B2 (en) 2009-03-09 2016-10-11 Bioatla, Llc Mirac proteins
EA201691430A1 (ru) 2009-06-08 2017-02-28 ЮСиЭл БИЗНЕС ПиЭлСи Лечение портальной гипертензии и восстановление функции печени с помощью l-орнитинфенилацетата
WO2012009545A1 (en) * 2010-07-14 2012-01-19 Cumberland Emerging Technologies, Inc Methods of treating hepatorenal syndrome and hepatic encephalopathy with thromboxane-a2 receptor antagonists
JP2012159356A (ja) * 2011-01-31 2012-08-23 Mochida Pharmaceut Co Ltd 敗血症診断用組合せマーカー
CN103254295A (zh) * 2013-05-31 2013-08-21 青岛国大生物制药股份有限公司 特利加压素的制备方法
HUE058066T2 (hu) * 2014-10-24 2022-06-28 Mallinckrodt Pharmaceuticals Ireland Ltd Terlipressin 1-es típusú hepatorenális szindróma kezelésére
JP2017014206A (ja) 2015-06-30 2017-01-19 ナノアンティバイオティクス，インコーポレイテッド 腹水の治療

Also Published As

Publication number Publication date
US10335452B2 (en) 2019-07-02
EP3209317A1 (en) 2017-08-30
JP2017534618A (ja) 2017-11-24
EP3978074A1 (en) 2022-04-06
ES2904492T3 (es) 2022-04-05
JP2022171795A (ja) 2022-11-11
JP2019199485A (ja) 2019-11-21
HUE058066T2 (hu) 2022-06-28
PT3978074T (pt) 2024-05-13
US20160113994A1 (en) 2016-04-28
JP6989571B2 (ja) 2022-01-05
CA2965325A1 (en) 2016-04-28
WO2016065117A1 (en) 2016-04-28
ES2987577T3 (es) 2024-11-15
JP6673915B2 (ja) 2020-03-25
PT3209317T (pt) 2022-01-19
EP3209317B1 (en) 2021-12-08
AU2015335855A1 (en) 2017-05-18
JP2021155433A (ja) 2021-10-07
SI3209317T1 (sl) 2022-05-31
EP3978074B1 (en) 2024-03-06
DK3209317T3 (da) 2022-02-07
CN107206049A (zh) 2017-09-26
HRP20220225T1 (hr) 2022-04-29
DK3978074T3 (da) 2024-05-13
FI3978074T3 (fi) 2024-05-20
JP7346494B2 (ja) 2023-09-19
EP3981420A1 (en) 2022-04-13
CN114028536A (zh) 2022-02-11
CN114028536B (zh) 2024-07-09
PL3978074T3 (pl) 2024-08-12
US20190328831A1 (en) 2019-10-31
PL3209317T3 (pl) 2022-05-23

Similar Documents

Publication Publication Date Title
CN107206049B (zh) 治疗患1型肝肾综合征的患者的方法
US20240366710A1 (en) Method of treating patients with hepatorenal syndrome type 1
US20220143132A1 (en) Method of treating patients with hepatorenal syndrome type 1
US20250276033A1 (en) Compositions for improving kidney function in patients with hepatorenal syndrome
US20200237856A1 (en) Method of treating patients with hepatorenal syndrome type 1
CN114980914A (zh) 低平均动脉压的1型肝肾综合征患者的治疗方法
AU2022288996A1 (en) Method of treating patients with hepatorenal syndrome type 1

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment
TG01 Patent term adjustment